Legend Biotech Corporation (LEGN)

Form 144 - Report of proposed sale of securities

Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Legend Biotech Corporation Announces Pricing of Public Offering

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Legend Biotech Corporation Announces Proposed Public Offering 

BRIDGEWATER, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (“Legend...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with...

Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

 Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Promising Phase 1 data for LB2501, a potential first‑in‑class CD19/CD20 dual‑targeting in vivo CAR-T therapy...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]